Takeda Pharmaceutical
298 hedge funds and large institutions have $1.04B invested in Takeda Pharmaceutical in 2021 Q4 according to their latest regulatory filings, with 61 funds opening new positions, 65 increasing their positions, 105 reducing their positions, and 52 closing their positions.
407% more call options, than puts
Call options by funds: $60.1M | Put options by funds: $11.9M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
17% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 52
2% more funds holding
Funds holding: 292 → 298 (+6)
1% less ownership
Funds ownership: 5.81% → 4.81% (-1%)
31% less capital invested
Capital invested by funds: $1.51B → $1.04B (-$465M)
38% less repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 105
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$69M |
| 2 |
BCP
BSN Capital Partners
London,
United Kingdom
|
+$65.6M |
| 3 |
Goldman Sachs
New York
|
+$16.8M |
| 4 |
HT
HAP Trading
New York
|
+$9.4M |
| 5 |
BlackRock
New York
|
+$5.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCM
Glenview Capital Management
New York
|
-$133M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$90.4M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$79.1M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$21.3M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$18.5M |
TAK Hedge Fund Activity: Q4 2021 in Review
298 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q4 2021, worth a combined $1.04B — down 31% from $1.51B a quarter earlier.
Buyers outnumbered sellers: 61 funds opened new TAK positions and 52 closed out — a net gain of 9 holders — while 65 added to existing stakes and 105 trimmed.
The largest buyer was Citigroup, adding an estimated $69M. The largest seller was Glenview Capital Management, exiting entirely with an estimated $133M sold.
- 298 institutional investors held Takeda Pharmaceutical (TAK) as of Q4 2021, up from 292 in Q3 2021.
- Funds reported $1.04B of Takeda Pharmaceutical stock for Q4 2021, down 31% quarter-over-quarter.
- 61 funds opened new Takeda Pharmaceutical positions in Q4 2021 and 52 closed out, a net change of +9 holders.
- The largest Takeda Pharmaceutical buyer in Q4 2021 was Citigroup, an estimated $69M added.
- The largest Takeda Pharmaceutical seller in Q4 2021 was Glenview Capital Management, an estimated $133M sold.
Based on aggregated 13F filings for Q4 2021.